Overview of ZUMA-2 Cohorts 1-3: Use of Brexu-cel in R/R MCL

Video content above is prompted by the following:

Five-Year Outcomes of Brexucabtagene Autoleucel in R/R MCL

Key Findings

• Long-term data from ZUMA-2 study demonstrate sustained efficacy of brexucabtagene autoleucel (brexu-cel) in patients with R/R MCL.
• Extended follow-up provides critical insights into the durability of response and long-term treatment outcomes.

Clinical Implications

• Continued durable responses suggest brexu-cel may represent a potentially transformative therapy for heavily pretreated patients with MCL.
• Five-year data challenge previous perceptions about the limited treatment options for R/R MCL.

Potential Treatment Sequencing Considerations

• The sustained response rates may:
• Encourage earlier consideration of CAR T-cell therapy in the treatment algorithm

• Prompt reevaluation of traditional sequential therapy approaches

• Support brexu-cel as a potentially meaningful bridge to subsequent interventions

Limitations and Considerations

• Long-term toxicity profile remains an important area of ongoing assessment.
• Patient selection criteria and individual variability remain critical factors in treatment decision-making.

Recommended Clinical Approach

• Carefully evaluate individual patient characteristics.
• Consider brexu-cel as a potentially promising option for patients with R/R MCL with limited alternative treatments.

Continued monitoring and individualized treatment planning remain paramount.